Bifogade filer
PDF
Kurs & Likviditet
Kalender
| 2024-11-22 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2024-11-21 | Årsstämma |
| 2024-11-17 | Kvartalsrapport 2025-Q1 |
| 2024-08-28 | Bokslutskommuniké 2024 |
| 2024-05-24 | Kvartalsrapport 2024-Q3 |
| 2024-02-22 | Kvartalsrapport 2024-Q2 |
| 2023-12-14 | Extra Bolagsstämma 2024 |
| 2023-11-24 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2023-11-23 | Årsstämma |
| 2023-11-17 | Kvartalsrapport 2024-Q1 |
| 2023-08-28 | Bokslutskommuniké 2023 |
| 2023-05-26 | Kvartalsrapport 2023-Q3 |
| 2023-05-17 | Extra Bolagsstämma 2023 |
| 2023-02-23 | Kvartalsrapport 2023-Q2 |
| 2022-11-25 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2022-11-24 | Årsstämma |
| 2022-11-11 | Kvartalsrapport 2023-Q1 |
| 2022-08-26 | Bokslutskommuniké 2022 |
| 2022-05-20 | Kvartalsrapport 2022-Q3 |
| 2022-02-25 | Kvartalsrapport 2022-Q2 |
| 2021-11-26 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2021-11-25 | Årsstämma |
| 2021-11-11 | Kvartalsrapport 2022-Q1 |
| 2021-08-27 | Bokslutskommuniké 2021 |
| 2021-06-17 | Extra Bolagsstämma 2022 |
| 2021-05-21 | Kvartalsrapport 2021-Q3 |
| 2021-03-02 | Extra Bolagsstämma 2021 |
| 2021-02-26 | Kvartalsrapport 2021-Q2 |
| 2020-11-27 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2020-11-26 | Årsstämma |
| 2020-11-12 | Kvartalsrapport 2021-Q1 |
| 2020-08-28 | Bokslutskommuniké 2020 |
| 2020-05-22 | Kvartalsrapport 2020-Q3 |
| 2020-02-28 | Kvartalsrapport 2020-Q2 |
| 2019-11-22 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2019-11-21 | Årsstämma |
| 2019-11-08 | Kvartalsrapport 2020-Q1 |
| 2019-08-30 | Bokslutskommuniké 2019 |
| 2019-05-17 | Kvartalsrapport 2019-Q3 |
| 2019-02-15 | Kvartalsrapport 2019-Q2 |
| 2018-11-16 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2018-11-15 | Årsstämma |
| 2018-11-09 | Kvartalsrapport 2019-Q1 |
| 2018-08-30 | Bokslutskommuniké 2018 |
| 2018-05-18 | Kvartalsrapport 2018-Q3 |
| 2018-02-16 | Kvartalsrapport 2018-Q2 |
| 2017-11-10 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2017-11-09 | Årsstämma |
| 2017-11-02 | Kvartalsrapport 2018-Q1 |
| 2017-08-18 | Bokslutskommuniké 2017 |
| 2017-05-12 | Kvartalsrapport 2017-Q3 |
| 2017-02-10 | Kvartalsrapport 2017-Q2 |
| 2017-01-19 | Extra Bolagsstämma 2018 |
| 2016-11-18 | Kvartalsrapport 2017-Q1 |
| 2016-11-11 | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2016-11-10 | Årsstämma |
| 2016-08-19 | Bokslutskommuniké 2016 |
| 2016-05-13 | Kvartalsrapport 2016-Q3 |
| 2016-02-12 | Kvartalsrapport 2016-Q2 |
| 2015-11-13 | Kvartalsrapport 2016-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hamlet Pharma AB has secured patent protection in Europe for milk-based nutraceutical products that have been prepared using a mild process that generates nutraceutically beneficial complexes. This is the subject of European patent EP 3295953 B1. The patent is valid until August 8, 2033.
The patent is based on extensive academic research and discoveries made by researchers at Lund University. With this patent, Hamlet Pharma AB continues to expand it's intellectual property portfolio to cover further areas where its key products show benefit.
`Bamlet is a molecule with beneficial effects. Through a neutraceutical preparation, Bamlet will reach consumers who can benefit from these effects " says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.
"We are very proud that this patent has been granted in Europe" says Mats Persson, CEO of Hamlet Pharma Ltd.
This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-11-2020 14:58 CET.
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57